Form 6-K Altamira Therapeutics For: Oct 04
- Wall Street ends mixed after job openings hint at cooling economy
- MongoDB delivers upbeat guidance after Q3 results beat
- U.S. job openings fall to 8.733 million in October - JOLTS report
- Hedge Funds were big sellers of Big Tech stocks last week - Morgan Stanley
- CVS Health adds 2% as 2024 revenue outlook tops estimates
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2023
Commission File Number: 001-36582
Altamira Therapeutics Ltd.
(Exact name of registrant as specified in its charter)
Clarendon House, 2 Church Street
Hamilton HM 11, Bermuda
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Special General Meeting of Shareholders
The Board of Directors of Altamira Therapeutics Ltd. intends to change the Company’s reporting currency from Swiss Francs to US Dollars as its common shares are publicly listed only in the US. It has therefore decided to call a Special General Meeting of Shareholders (“Special General Meeting”) in order to propose to change the currency denomination of the Company’s authorized share capital from CHF to US Dollars, at the exchange rate prevailing on such date as determined by the Board of Directors of the Company, with effect from such date as determined by the Board of Directors of the Company and with the Board of Directors of the Company being authorized to determine such effective date (the “Effective Date”); (ii) with effect from the Effective Date, reduce the issued share capital of the Company by reducing the par value of each common share in issue to USD 0.0001, and to credit the amount of the reduction to the contributed surplus account of the Company; and (iii) with effect from the Effective Date, to reduce the authorized share capital of the Company to USD 12,000 divided into 100,000,000 common shares of USD 0.0001 par value each and 20,000,000 preference shares of USD 0.0001 par value each, provided the Company satisfies the requirements of section 46(2) of the Companies Act 1981, as amended of Bermuda on the Effective Date.
The Special General Meeting will be held on October 31, 2023, 8:30 AM Atlantic Daylight Time at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Altamira Therapeutics Ltd.|
|Date: October 04, 2023||By:||/s/ Thomas Meyer|
|Title:||Chief Executive Officer|
|99.1||Notice to Shareholders dated October 04, 2023|
|99.2||Proxy Card for the Special General Meeting of Shareholders|
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Altamira Therapeutics to Host Investor & Business Update Call on December 11th
- George Washington University Competition Law Center and Crowell & Moring Host Fifth Annual Antitrust and Tech Conference
- Organto Provides Update on Private Placement Financing
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!